Burling Wealth Partners LLC Sells 7,308 Shares of Zoetis Inc. $ZTS

Burling Wealth Partners LLC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 24.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,488 shares of the company’s stock after selling 7,308 shares during the quarter. Burling Wealth Partners LLC’s holdings in Zoetis were worth $2,829,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in ZTS. Nordea Investment Management AB grew its stake in shares of Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after buying an additional 2,179,578 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after buying an additional 10,434 shares in the last quarter. Seilern Investment Management Ltd grew its stake in shares of Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after buying an additional 261,155 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Zoetis by 134.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after buying an additional 935,432 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp grew its stake in shares of Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after buying an additional 18,040 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 0.9%

ZTS opened at $79.64 on Thursday. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The company has a market capitalization of $33.39 billion, a P/E ratio of 13.21, a P/E/G ratio of 1.29 and a beta of 0.87. The stock has a fifty day moving average of $109.69 and a 200-day moving average of $119.37.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the prior year, the business posted $1.48 EPS. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.88 EPS for the current year.

Insider Buying and Selling

In related news, Director Michael B. Mccallister purchased 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on ZTS shares. BTIG Research reaffirmed a “buy” rating and set a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. UBS Group cut their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Stifel Nicolaus set a $105.00 price target on Zoetis in a report on Friday, May 8th. Citigroup cut their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday. Finally, JPMorgan Chase & Co. cut their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $134.75.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.